Merck ends development of Januvia-Lipitor combo

Associated Press Modified: November 13, 2012 at 1:00 pm •  Published: November 13, 2012

NEW YORK (AP) — Merck & Co. has disclosed that it is ending development of a pill that combines its diabetes drug Januvia with atorvastatin, the main ingredient in Lipitor.

Merck cited unspecified business reasons for ending clinical work on the pill, which was designated MK-0431E. It disclosed the move in a form filed with the Securities and Exchange Commission on Friday.

Januvia is the Whitehouse Station, N.J., company's best-selling drug. In the third quarter revenue from Januvia rose 15 percent to $975 million. That was 50 percent more revenue than its next biggest product, the cholesterol drug Zetia.

Lipitor is marketed by Pfizer Inc. It was the best-selling drug in history, but lost patent protection about a year ago, allowing generic versions to reach the market.

Shares of Merck rose 8 cents to $44.09 in afternoon trading.

Trending Now


  1. 1
    Colorado Is Consuming Way More Pot Than Anyone Ever Believed
  2. 2
    What Dan Gilbert said to LeBron James to get him to return to Cleveland
  3. 3
    Female Yahoo Exec Sued By a Female Employee for Sexual Harassment
  4. 4
    A company wants you to experiment on Facebook — by quitting
  5. 5
    LeBron's face vandalized on Miami mural that took 2+ years to create
+ show more